All Stories

  1. DOAC plasma levels measured by chromogenic anti‐Xa assays and HPLC‐UV in apixaban‐ and rivaroxaban‐treated patients from the START‐Register
  2. An in vitro study to investigate the interference of enoxaparin on plasma levels of direct oral factor Xa inhibitors measured by chromogenic assays
  3. Comparison of five specific assays for determination of dabigatran plasma concentrations in patients enrolled in the START-Laboratory Register
  4. Endothelial activation in patients with superficial vein thrombosis (SVT) of the lower limbs
  5. Thrombin generation and intracranial atherosclerotic disease in patients with a transient ischaemic attack
  6. Variability of cut-off values for the detection of lupus anticoagulants: results of an international multicenter multiplatform study
  7. Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a multicenter/multiplatform study
  8. Diagnostic Accuracy of a New d-Dimer Assay (Sclavo Auto d-Dimer) for Exclusion of Deep Vein Thrombosis in Symptomatic Outpatients
  9. Measurement of factor XIII (FXIII) activity by an automatic ammonia release assay using iodoacetamide blank-procedure: no more overestimation in the low activity range and better detection of severe FXIII deficiencies
  10. Evaluation of a chemiluminescent immunoassay, the HemosIL AcuStar D-Dimer, in outpatients with clinically suspected deep venous thrombosis
  11. D-dimer for the diagnosis of upper extremity deep and superficial venous thrombosis
  12. Rivaroxaban in the Treatment of Heparin-Induced Thrombocytopenia
  13. D-dimer, FVIII and thrombotic burden in the acute phase of deep vein thrombosis in relation to the risk of post-thrombotic syndrome
  14. Inherited and acquired thrombophilic alterations in patients with superficial vein thrombosis of lower limbs
  15. D-dimer use for deep venous thrombosis exclusion in elderly patients: a comparative analysis of three different approaches to establish cut-off values for an assay with results expressed in D-dimer units
  16. Influence of proband's characteristics on the risk for venous thromboembolism in relatives with factor V Leiden or prothrombin G20210A polymorphisms
  17. The Wells rule and D-dimer for the diagnosis of isolated distal deep vein thrombosis
  18. The influence of VKORC1 3730 G > A polymorphism on warfarin dose: reply
  19. The F11 rs2289252 polymorphism is associated with FXI activity levels and APTT ratio in women with thrombosis
  20. A new warfarin dosing algorithm including VKORC1 3730 G > A polymorphism: comparison with results obtained by other published algorithms
  21. Age and gender specific cut-off values to improve the performance of d-dimer assays to predict the risk of venous thromboembolism recurrence
  22. D-dimer and residual vein obstruction as risk factors for recurrence during and after anticoagulation withdrawal in patients with a first episode of provoked deep-vein thrombosis
  23. No early signs of atherosclerotic alterations in carriers of inherited thrombophilia
  24. Evaluation of a new automated panel of assays for the detection of anti-PF4/heparin antibodies in patients suspected of having heparin-induced thrombocytopenia
  25. Thalidomide-dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin
  26. Multicenter evaluation of a new quantitative highly sensitive D-dimer assay, the Hemosil® D-dimer HS 500, in patients with clinically suspected venous thromboembolism
  27. Thrombophilic risk factors and peripheral arterial disease severity
  28. Pharmacodynamics of low molecular weight heparin in patients undergoing bariatric surgery: A prospective, randomised study comparing two doses of parnaparin (BAFLUX STUDY)
  29. G20210A Prothrombin Mutation and Critical Limb Ischaemia in Patients with Peripheral Arterial Disease
  30. Different cut-off values of quantitative D-dimer methods to predict the risk of venous thromboembolism recurrence: a post-hoc analysis of the PROLONG study
  31. Influence of low-density lipoprotein (LDL) receptor-related protein and ABO blood group genotypes on factor XI levels
  32. D-dimer and factor VIII are independent risk factors for recurrence after anticoagulation withdrawal for a first idiopathic deep vein thrombosis
  33. Abnormally short activated partial thromboplastin time values are associated with increased risk of recurrence of venous thromboembolism after oral anticoagulation withdrawal
  34. D-dimer levels in combination with residual venous obstruction and the risk of recurrence after anticoagulation withdrawal for a first idiopathic deep vein thrombosis
  35. Poor anticoagulation quality in the first 3 months after unprovoked venous thromboembolism is a risk factor for long-term recurrence
  36. A new rapid bedside assay for d-dimer measurement (Simplify d-dimer) in the diagnostic work-up for deep vein thrombosis
  37. Additive thrombin inhibition by fast moving heparin and dermatan sulfate explains the anticoagulant effect of sulodexide, a natural mixture of glycosaminoglycans
  38. A new rapid bedside assay for quantitative testing of D-Dimer (Cardiac D-Dimer) in the diagnostic work-up for deep vein thrombosis
  39. Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy